SCHEMBL7658523

SCHEMBL7658523

Cc1cc2c(s1)Oc1ccccc1NC2=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.47
POLB P06746 3/20 0.47
TDP1 Q9NUW8 2/20 0.47
TP53 P04637 2/20 0.47
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
L3MBTL1 Q9Y468 3/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 2/20 0.43
ACVR1 Q04771 2/20 0.42
LRRK2 Q5S007 2/20 0.42
ROS1 P08922 1/20 0.42
CDK5 Q00535 1/20 0.42
ALOX5 P09917 2/20 0.42
CSNK1G1 Q9HCP0 1/20 0.40
PDGFRA P16234 1/20 0.39
FER P16591 1/20 0.39
LTK P29376 1/20 0.39
CDK8 P49336 1/20 0.39
DYRK1B Q9Y463 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimethylamine SCHEMBL7666545 0.96 MAPT (0.44) MAPTPOLBTDP1TP53MEN1
SCHEMBL7659353 0.84 MMP12 (0.47) MAPTPOLBTDP1TP53ALDH1A1
SCHEMBL7658309 0.84 ALDH1A1 (0.46) MAPTPOLBTDP1TP53MEN1
SCHEMBL7658693 0.83 LMNA (0.44) MAPTPOLBTDP1TP53MEN1
SCHEMBL7653766 0.82 MAPT (0.46) MAPTPOLBTDP1TP53MEN1
SCHEMBL7661726 0.82 MAPT (0.43) MAPTPOLBTDP1TP53MEN1
SCHEMBL7661672 0.82 CES1 (0.42) MAPTTP53ALDH1A1LMNALRRK2
SCHEMBL7666555 0.82 KMT2A (0.37) MAPTMEN1KMT2AALDH1A1LMNA
SCHEMBL7660369 0.82 TGM2 (0.37) MEN1KMT2ALRRK2
SCHEMBL7664938 0.82 CES1 (0.42) MAPTPOLBTP53LMNALRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US claimed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP claimed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885POLB 1763/4885TDP1 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.